Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine.

[1]  R. Caprioli,et al.  Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. , 2007, Journal of molecular and cellular cardiology.

[2]  Y. Tomino,et al.  Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. , 2007, Metabolism: clinical and experimental.

[3]  M. Zhang,et al.  Redox signalling involving NADPH oxidase-derived reactive oxygen species. , 2006, Biochemical Society transactions.

[4]  G. Striker,et al.  Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. , 2006, Kidney International.

[5]  J. Donoso,et al.  Inhibition of Glycosylation Processes: the Reaction between Pyridoxamine and Glucose , 2005, Chemistry & biodiversity.

[6]  Paul J Thornalley,et al.  Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes , 2005, Diabetologia.

[7]  R. Nagaraj,et al.  3-Hydroxykynurenine-mediated Modification of Human Lens Proteins , 2005, Journal of Biological Chemistry.

[8]  Michael Brownlee,et al.  The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.

[9]  B. Hudson,et al.  Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage , 2005, Cellular and Molecular Life Sciences CMLS.

[10]  V. Monnier,et al.  Glucosepane Is a Major Protein Cross-link of the Senescent Human Extracellular Matrix , 2005, Journal of Biological Chemistry.

[11]  K. Nair,et al.  Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. , 2005, Diabetes care.

[12]  S. Kyuwa,et al.  Amelioration of the β‐cell dysfunction in diabetic APA hamsters by antioxidants and AGE inhibitor treatments , 2004, Diabetes/metabolism research and reviews.

[13]  E. Barrett.  Diabetes Epidemic Is a Worldwide Threat , 2004 .

[14]  M. Argirova,et al.  Activation of protein-bound copper ions during early glycation: study on two proteins. , 2003, Archives of biochemistry and biophysics.

[15]  R. Khalifah,et al.  Modification of Proteins In Vitro by Physiological Levels of Glucose , 2003, Journal of Biological Chemistry.

[16]  Anne Dawnay,et al.  Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. , 2003, The Biochemical journal.

[17]  J. Baynes,et al.  Maillard reaction products in tissue proteins: New products and new perspectives , 2003, Amino Acids.

[18]  Sushil K. Jain,et al.  Effect of high-glucose levels on protein oxidation in cultured lens cells, and in crystalline and albumin solution and its inhibition by vitamin B6 and N-acetylcysteine: its possible relevance to cataract formation in diabetes. , 2002, Free radical biology & medicine.

[19]  M. Nangaku,et al.  Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. , 2002, Journal of the American Society of Nephrology : JASN.

[20]  Alan W. Stitt,et al.  The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. , 2002, Diabetes.

[21]  K. Biemel,et al.  Identification and Quantification of Major Maillard Cross-links in Human Serum Albumin and Lens Protein , 2002, The Journal of Biological Chemistry.

[22]  S. Gygi,et al.  Automation of nanoscale microcapillary liquid chromatography-tandem mass spectrometry with a vented column. , 2002, Analytical chemistry.

[23]  M. Steffes,et al.  Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.

[24]  D. L. Price,et al.  Chelating Activity of Advanced Glycation End-product Inhibitors* , 2001, The Journal of Biological Chemistry.

[25]  M. Chance,et al.  Determination of macromolecular folding and structure by synchrotron x-ray radiolysis techniques. , 2001, Analytical biochemistry.

[26]  S. Jain,et al.  Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. , 2001, Free radical biology & medicine.

[27]  A. Jenkins,et al.  Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions , 2000, The Journal of Biological Chemistry.

[28]  Paul J Thornalley,et al.  Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. , 1999, The Biochemical journal.

[29]  M. Obrenovich,et al.  Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. , 1999, Biochemical and biophysical research communications.

[30]  S. Genuth,et al.  Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Contro , 1999, Diabetes.

[31]  G. Glinsky,et al.  Superoxide free radical generation by Amadori compounds: the role of acyclic forms and metal ions. , 1999, Chemical research in toxicology.

[32]  J. Baynes,et al.  Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.

[33]  K. Schey,et al.  Identification of tryptophan oxidation products in bovine α‐crystallin , 1998, Protein science : a publication of the Protein Society.

[34]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[35]  F. A. Shamsi,et al.  Immunological Evidence for Methylglyoxal-derived Modifications in Vivo , 1998, The Journal of Biological Chemistry.

[36]  Yong Ming Li.  Glycation Ligand Binding Motif in Lactoferrin , 1998 .

[37]  D. Kerjaschki,et al.  Reactive oxygen species cause direct damage of Engelbreth-Holm-Swarm matrix. , 1997, The American journal of pathology.

[38]  T. Miyazaki,et al.  Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. , 1997, The Journal of clinical investigation.

[39]  A. Booth,et al.  In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs) , 1997, The Journal of Biological Chemistry.

[40]  N. C. Price,et al.  Glucose modification of human serum albumin: a structural study. , 1997, Free radical biology & medicine.

[41]  J. Mott,et al.  Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies. , 1996, Biochemistry.

[42]  N. Blough,et al.  Combined liquid chromatography/mass spectrometry of the radical adducts of a fluorescamine-derivatized nitroxide. , 1996, Analytical chemistry.

[43]  A. J. Furth,et al.  Mixed dimers formed by crosslinking of native and glycated proteins in the absence of free sugar. , 1996, Biochemical and biophysical research communications.

[44]  Motoko Takahashi,et al.  Fragmentation of ceruloplasmin following non-enzymatic glycation reaction. , 1995, Journal of biochemistry.

[45]  Yong Ming Li,et al.  Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation–modified proteins to a conserved motif , 1995, Nature Medicine.

[46]  V. Monnier,et al.  Mechanism of Protein Modification by Glyoxal and Glycolaldehyde, Reactive Intermediates of the Maillard Reaction (*) , 1995, The Journal of Biological Chemistry.

[47]  J. Yates,et al.  Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. , 1995, Analytical chemistry.

[48]  J. Baynes,et al.  Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. , 1995, Biochemistry.

[49]  J. Richardson,et al.  Formation of reactive intermediates from Amadori compounds under physiological conditions. , 1995, Archives of biochemistry and biophysics.

[50]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[51]  R. Hosmane,et al.  A fluorophore-containing nitroxide as a probe to detect superoxide and hydroxyl radical generated by stimulated neutrophils. , 1993, Analytical biochemistry.

[52]  P. Guptasarma,et al.  Hydroxyl radical mediated damage to proteins, with special reference to the crystallins. , 1992, Biochemistry.

[53]  T. Nakazawa,et al.  Site-specific 13C-labeling of Trp 62 in hen egg-white lysozyme: preparation and 13C-NMR titration of [delta 1-13C]Trp 62-lysozyme. , 1991, Journal of biochemistry.

[54]  S. Wolff,et al.  Oxidative glycation and free radical production: a causal mechanism of diabetic complications. , 1991, Free radical research communications.

[55]  N. Blough,et al.  Fluorescence detection of carbon-centered radicals in aqueous solution. , 1990, Free radical research communications.

[56]  S. Tsuchiya,et al.  Superoxide production from nonenzymatically glycated protein , 1988, FEBS letters.

[57]  T. S. Stevens,et al.  Porous ceramic bed supports for fused silica packed capillary columns used in liquid chromatography , 1987 .

[58]  S P Wolff,et al.  Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. , 1987, The Biochemical journal.

[59]  B. Halliwell,et al.  Free radicals in biology and medicine , 1985 .

[60]  R. Ragone,et al.  Determination of tyrosine exposure in proteins by second-derivative spectroscopy. , 1984, Biochemistry.

[61]  J. Baynes,et al.  Nonenzymatic glucosylation and glucose-dependent cross-linking of protein. , 1983, The Journal of biological chemistry.

[62]  M. F. Richardson,et al.  Reactions of metal ions with vitamins. IV. The crystal structure of a zinc complex of pyridoxamine (Vitamin B6) , 1980 .

[63]  J. Baynes,et al.  Enhanced nonenzymatic glucosylation of human serum albumin in diabetes mellitus. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[64]  N. Sharon,et al.  Mechanism of lysozyme action. , 1969, Science.

[65]  A. Martell,et al.  Stabilities of metal chelates of pyridoxamine. , 1957, Archives of biochemistry and biophysics.

[66]  D. Shugar.  The measurement of lysozyme activity and the ultra-violet inactivation of lysozyme. , 1952, Biochimica et biophysica acta.